Acoramidis Demonstrates Superiority Over Tafamidis, Reducing Hospitalizations by 34% in ATTR-CM
BBIO has more than doubled off its 52-week low of $31.77.
Summary
BridgeBio Pharma announced new, positive data from its Phase 3 ATTRibute-CM study for acoramidis, presented at Heart Failure 2026. The data demonstrated disease-modifying effects, including a significant reduction in sTTR variability and early, sustained reductions in outpatient worsening heart failure. Crucially, an indirect comparison showed acoramidis achieved a statistically significant 34% reduction in cardiovascular hospitalizations compared to tafamidis, a key competitor, along with a favorable mortality trend and comparable safety. This robust clinical data, particularly the comparative efficacy against an established treatment, significantly strengthens acoramidis's market position and potential for broader adoption. This follows recent marketing authorization for acoramidis in Brazil and strong Q1 financial results, building positive momentum for the company. Investors will now closely monitor further regulatory approvals and commercialization updates.
At the time of this announcement, BBIO was trading at $67.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.1B. The 52-week trading range was $31.77 to $84.94. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.